RPI 78M

Drug Profile

RPI 78M

Alternative Names: Alpha-cobratoxin-derived peptide; Alpha-Immunokine; Receptin; RPI-78M

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Bio Therapeutics
  • Developer ReceptoPharm
  • Class Proteins
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis
  • Suspended Adrenomyeloneuropathy
  • Discontinued Herpes simplex virus infections; Rabies

Most Recent Events

  • 31 May 2017 Nutra Pharma Corporation and University of Maryland agree to co-develop RPI 78M for phase II trials in Multiple sclerosis
  • 09 Sep 2015 Phase-I clinical trials in Multiple sclerosis in USA (SC)
  • 08 Sep 2015 RPI 78M receives Orphan Drug status for Multiple sclerosis (In children) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top